Galapagos NV

(NASDAQ:GLPG)

Latest On Galapagos NV (GLPG):

Date/Time Type Description Signal Details
2023-05-06 09:51 ESTNewsGalapagos Stands Strong On Jyseleca Positive Clinical DataN/A
2023-05-05 21:26 ESTNewsGalapagos NV (GLPG) Q1 2023 Earnings Call TranscriptN/A
2023-05-04 19:34 ESTNewsGalapagos GAAP EPS of €0.40, revenue of €178.9MN/A
2023-05-03 18:15 ESTNewsGalapagos Q1 2023 Earnings PreviewN/A
2023-05-03 05:16 ESTNewsGalapagos announces departure of COO and CFO Bart FiliusN/A
2023-03-30 21:01 ESTNewsGalapagos to transfer drug discovery and research activities in France to NovAliXN/A
2023-02-24 11:36 ESTNewsGalapagos NV (GLPG) Q4 2022 Earnings Call TranscriptN/A
2023-02-23 22:33 ESTNewsGalapagos reports FY 2022 results, sees further reduction of cash burn in FY 2023N/A
2023-02-11 10:09 ESTNewsGalapagos: Crohn's Disease Trial Failure, Still Maintaining A Buy RatingN/A
2023-02-09 18:47 ESTNewsGalapagos stock dips as Jyseleca fails phase 3 trial as induction therapy in Crohn's disease, cancels plan for EU filingN/A
2023-02-08 02:22 ESTNewsGalapagos: Deeply Into Negative EV Territory, Exciting BD Optionality, BuyN/A
2022-12-31 07:11 ESTNewsGalapagos: Slow Transformation, But Led By An ExpertN/A
2022-11-07 11:28 ESTNewsGalapagos downgraded to market perform at Raymond James on unclear path forwardN/A
2022-11-03 19:29 ESTNewsGalapagos GAAP EPS of -€0.16, revenue of €410.2MN/A
2022-11-03 02:25 ESTNewsGalapagos Q3 2022 Earnings PreviewN/A
2022-10-10 20:03 ESTNewsGalapagos: Trading At Discount To Cash With A Fast-Growing Marketed ProductN/A
2022-10-03 19:25 ESTNewsEMA panel approves amending label for Galapagos' Jyseleca on testicular function effectsN/A
2022-09-09 14:41 ESTNewsGalapagos cut at Morgan Stanley on positive but slow transformationN/A
2022-08-06 18:23 ESTNewsGalapagos NV (GLPG) CEO Paul Stoffels on Q2 2022 Results - Earnings Call TranscriptN/A
2022-08-04 20:20 ESTNewsGalapagos GAAP EPS of -€0.49, revenue of €274MN/A
2022-07-25 21:27 ESTNewsGalapagos stock dips after Jefferies slashes rating citing challenges aheadN/A
2022-06-21 19:06 ESTNewsGalapagos to enter cell therapy space with acquisition of CellPoint and AboundBioN/A
2022-05-30 23:31 ESTNewsMorgan Stanley updates biotechs with negative enterprise values & 2022 catalystsN/A
2022-05-25 07:04 ESTNewsGalapagos to license drug targets for inflammatory bowel disease from Scipher MedicineN/A
2022-05-20 09:10 ESTNewsGalapagos: Can The Company Turn Around?N/A
2022-05-06 13:39 ESTNewsGalapagos GAAP EPS of -€0.20, revenue of €136.3MN/A
2022-05-06 13:39 ESTNewsGalapagos NV (GLPG) CEO Paul Stoffels on Q1 2022 Results - Earnings Call TranscriptN/A
2022-05-06 13:38 ESTNewsGalapagos NV 2022 Q1 - Results - Earnings Call PresentationN/A
2022-05-05 15:51 ESTNewsGalapagos Q1 2022 Earnings PreviewN/A
2022-03-28 07:24 ESTNewsGilead, Galapagos' Jyseleca gets approval in Japan for expanded use in ulcerative colitisN/A
2022-02-25 18:23 ESTNewsGalapagos NV (GLPG) CEO Onno van de Stolpe on Q4 2021 Results - Earnings Call TranscriptN/A
2022-02-25 01:06 ESTNewsGalapagos GAAP EPS of -€1.58, revenue of €484.85MN/A
2022-02-24 05:28 ESTNewsGalapagos Q4 2021 Earnings PreviewN/A
2022-02-22 14:27 ESTNewsGalapagos: A History Of Disruptive FailuresN/A
2022-01-28 00:18 ESTNewsGalapagos at a six-month high after naming former J&J science chief as CEON/A
2022-01-27 07:39 ESTNewsGalapagos creates 1M subscription rights; stock rises 9%N/A
2022-01-26 14:26 ESTNewsEinhorn's Greenlight discloses positions in Global Payments, Capri, Galapagos, ODP Corp.N/A
2022-01-19 05:53 ESTNewsGalapagos' Jyseleca wins UK marketing authorization for ulcerative colitisN/A
2022-01-09 00:57 ESTNewsBiogen, Galapagos and Ultragenyx among key biotech calls at Morgan Stanley for 2022N/A
2021-12-04 00:46 ESTNewsGalapagos announces increase in share capital with subscription right exercisesN/A
2021-12-02 09:17 ESTNewsGalapagos: The Investment Thesis Is More Appealing Than EverN/A
2021-11-15 16:53 ESTNewsGalapagos wins EU approval for Jyseleca for ulcerative colitisN/A
2021-11-08 23:33 ESTNewsGalapagos rises as analysts highlight a major catalyst aheadN/A
2021-11-05 17:29 ESTNewsGalapagos NV's (GLPG) CEO Onno van de Stolpe on Q3 2021 Results - Earnings Call TranscriptN/A
2021-11-04 20:49 ESTNewsGalapagos reports Q3 resultsN/A
2021-11-03 23:37 ESTNewsGalapagos Q3 2021 Earnings PreviewN/A
2021-10-04 18:03 ESTNewsGalapagos posts results from post-hoc analyses of filgotinib in ulcerative colitisN/A
2021-09-22 14:07 ESTNewsGalapagos' filgotinib wins positive CHMP opinion for treatment of ulcerative colitisN/A
2021-08-19 18:51 ESTNewsGalapagos lowered to equal weight at Barclays; doubts acquisition driven upsideN/A
2021-08-08 04:48 ESTNewsGalapagos NV (GLPG) CEO Onno van de Stolpe on Q2 2021 Results - Earnings Call TranscriptN/A

About Galapagos NV (GLPG):

Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes various small molecule medicines. Its clinical stage programs include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, Sjögren's syndrome, ankylosing spondylitis, psoriatic arthritis, cutaneous lupus erythematosus, lupus membranous nephropathy, and uveitis. The company's clinical stage programs also comprise GLPG1690, an autotaxin inhibitor that is in ISABELA I and II trials for idiopathic pulmonary fibrosis (IPF), and NOVESA Phase II proof-of-concept trial for systemic sclerosis; and GLPG1205, a GPR84 inhibitor, which is in the PINTA Phase II proof of concept trial for treating IPF. In addition, it engages in the development of GLPG1972, which is in the ROCCELLA Phase 2b trial for treating osteoarthritis; and Toledo molecules, including GLPG3312, GLPG3970, and GLPG4399 for inflammation. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; Novartis Pharma AG; Les Laboratoires Servier and Institut de Recherches Servier; and Ryvu Therapeutics S.A. Galapagos NV was founded in 1999 and is headquartered in Mechelen, Belgium.

See Advanced Chart

General

  • Name Galapagos NV
  • Symbol GLPG
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Fiscal Year EndDecember
  • IPO Date2005-05-06
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.glpg.com
View More

Valuation

  • Trailing PE 60.65
  • Price/Sales (Trailing 12 Mt.) 9.78
  • Price/Book (Most Recent Quarter) 1.69
  • Enterprise Value Revenue 1.18
  • Enterprise Value EBITDA 3.11
View More

Financials

  • Most Recent Quarter 2020-09-30
  • Current Year EPS Estimate -$4.89
  • Next Year EPS Estimate -$4.50
  • Next Quarter EPS Estimate -$0.28
  • Profit Margin -58%
  • Return on Assets -2%
  • Return on Equity -11%
  • Earnings Per Share -$1.69
  • Revenue Per Share $0
  • Gross Profit 6.6 million
  • Quarterly Earnings Growth -77.6%
View More

Highlights

  • Market Capitalization 5.28 billion
  • Analyst Target Price $93.67
  • Book Value Per Share $25.49
View More

Share Statistics

  • Shares Outstanding 65.41 million
  • Shares Float 43.14 million
  • % Held by Insiders <1%
  • % Held by Institutions 11.77%
  • Shares Short 936943
  • Shares Short Prior Month 966729
  • Short Ratio 2.3
  • Short % of Shares Outstanding 1%
View More

Technicals

  • Beta 0.28
  • 52 Week High $233.14
  • 52 Week Low $79.59
  • 50 Day Moving Average 90.41
  • 200 Day Moving Average 114.01
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Galapagos NV (GLPG) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Galapagos NV (GLPG) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-02-18-$1.06-$1.5330.28%
2020-09-302020-11-05$131.82 million-$1.49-$0.99-51.08%
2020-06-302020-08-06$N/A-$2.10-$0.85-147.49%
2020-03-312020-05-07$N/A-$0.85-$0.862.01%
2019-12-312020-02-20$160.81 million-$2.34-$0.79-193.91%
2019-09-302019-10-24$701.86 million$7.05$3.29114.55%
2019-06-302019-07-25$76.28 million-$0.97-$1.2522.41%
2019-03-312019-04-25$45.88 million-$0.99-$1.022.59%
2018-12-312019-02-21$129.35 million$0.31-$0.90134.1%
2018-09-302018-10-24$119.48 million$0.32-$1.10129.08%
2018-06-302018-08-02$66.38 million-$0.49-$1.0051.42%
2018-03-312018-04-25$55.24 million-$0.89-$1.1119.74%
2017-12-312018-02-22$61.81 million-$0.73-$0.9120.04%
2017-09-302017-10-26$42.3 million-$0.84-$0.9310.37%
2017-06-302017-07-27$40.69 million-$0.86-$0.67-29.5%
2017-03-312017-04-27$42.65 million-$0.32-$0.5946.03%
2016-12-312017-02-23$86.89 million$1.05$0.10897.14%
2016-09-302016-10-27$19.3 million-$0.57-$0.6614.05%
2016-06-302016-07-28$36.92 million-$0.11-$0.2146.22%
2016-03-312016-04-28$16.88 million$0.89$1.30-31.2%
2015-12-312016-03-03$13.08 million-$1.69-$0.84-101.49%
2015-09-302015-11-13$11.52 million-$0.72$4.06-117.73%
2015-06-302015-08-06$19.68 million-$0.59-$0.35-68.57%

Galapagos NV (GLPG) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Galapagos NV (GLPG) Chart:

Galapagos NV (GLPG) News:

Below you will find a list of latest news for Galapagos NV (GLPG) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Galapagos NV (GLPG) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2025-10-1712.50CALL0 00TRUE00
2025-10-17150CALL0 00TRUE00
2025-10-1717.50CALL0 00TRUE00
2025-10-17200CALL0 00TRUE00
2025-10-1722.50CALL0 00TRUE00
2025-10-17258.2CALL0 550TRUE00
2025-10-1727.56.2CALL0 20TRUE00
2025-10-17303.1CALL0 6370TRUE00
2025-10-1732.52.15CALL0 6037.51TRUE00
2025-10-17350.2CALL0 75144.21FALSE00
2025-10-1737.50.81CALL2 452.46FALSE0.810
2025-10-17400.65CALL0 8189.78FALSE00
2025-10-1742.50CALL0 0207.99FALSE00
2025-10-17450CALL0 0224.19FALSE00
2025-10-1747.50CALL0 0238.8FALSE00
2025-10-17500CALL0 0252.12FALSE00
2025-10-1712.50PUT0 0628.66FALSE00
2025-10-17150PUT0 0529.02FALSE00
2025-10-1717.50PUT0 0451.61FALSE00
2025-10-17200PUT0 2387.98FALSE00
2025-10-1722.50PUT0 1333.57FALSE00
2025-10-17250PUT0 41285.57FALSE00
2025-10-1727.51.1PUT0 62242.07FALSE00
2025-10-17301.96PUT0 30470.9FALSE00
2025-10-1732.50.65PUT0 22929.85FALSE00
2025-10-17350PUT0 059.39TRUE00
2025-10-1737.50PUT0 042.54TRUE00
2025-10-17400PUT0 069.06TRUE00
2025-10-1742.50PUT0 077.81TRUE00
2025-10-17450PUT0 092.74TRUE00
2025-10-1747.50PUT0 0102.05TRUE00
2025-10-17500PUT0 0112.62TRUE00
2025-11-2117.50CALL0 00TRUE00
2025-11-21200CALL0 00TRUE00
2025-11-2122.50CALL0 058TRUE00
2025-11-21250CALL0 00TRUE00
2025-11-2127.50CALL0 00TRUE00
2025-11-21300CALL0 00TRUE00
2025-11-2132.50CALL0 026.09TRUE00
2025-11-21350CALL0 094.17FALSE00
2025-11-2137.50CALL0 0110.58FALSE00
2025-11-21400CALL0 0124.43FALSE00
2025-11-2142.50CALL0 0136.5FALSE00
2025-11-21450CALL0 0147.22FALSE00
2025-11-2147.50CALL0 0156.9FALSE00
2025-11-2117.50PUT0 0299.13FALSE00
2025-11-21200PUT0 0257.1FALSE00
2025-11-2122.50PUT0 0221.17FALSE00
2025-11-21250PUT0 0189.49FALSE00
2025-11-2127.50PUT0 0160.79FALSE00
2025-11-21300PUT0 0134.09FALSE00
2025-11-2132.50PUT0 062.29FALSE00
2025-11-21350PUT0 040.8TRUE00
2025-11-2137.50PUT0 036.4TRUE00
2025-11-21400PUT0 042.81TRUE00
2025-11-2142.50PUT0 052.49TRUE00
2025-11-21450PUT0 059.61TRUE00
2025-11-2147.50PUT0 071.93TRUE00
2026-01-1612.50CALL0 00TRUE00
2026-01-16150CALL0 058.97TRUE00
2026-01-1617.50CALL0 00TRUE00
2026-01-16200CALL0 00TRUE00
2026-01-1622.50CALL0 00TRUE00
2026-01-16250CALL0 00TRUE00
2026-01-1627.50CALL0 015.16TRUE00
2026-01-16302.95CALL0 1621.13TRUE00
2026-01-1632.52.9CALL0 4614.21TRUE00
2026-01-16351.8CALL55 11225.65FALSE1.80
2026-01-1637.50.75CALL0 147.46FALSE00
2026-01-16400.85CALL0 789.31FALSE00
2026-01-1642.50CALL0 098.11FALSE00
2026-01-16450CALL0 0105.93FALSE00
2026-01-1647.50CALL0 0112.98FALSE00
2026-01-16500CALL0 0119.39FALSE00
2026-01-1612.50PUT0 0303.07FALSE00
2026-01-16150PUT0 0255.19FALSE00
2026-01-1617.50PUT0 0218.03FALSE00
2026-01-16200PUT0 0187.52FALSE00
2026-01-1622.50PUT0 0110.94FALSE00
2026-01-16250PUT0 0120.6FALSE00
2026-01-1627.50PUT0 0117.67FALSE00
2026-01-16301.58PUT0 1098.34FALSE00
2026-01-1632.50PUT0 046.18FALSE00
2026-01-16350PUT0 036.3TRUE00
2026-01-1637.50PUT0 034.1TRUE00
2026-01-16408.25PUT0 134.81TRUE00
2026-01-1642.50PUT0 041.36TRUE00
2026-01-16450PUT0 046.95TRUE00
2026-01-1647.50PUT0 050.63TRUE00
2026-01-16500PUT0 057.19TRUE00
2026-04-1717.50CALL0 00TRUE00
2026-04-17200CALL0 00TRUE00
2026-04-1722.50CALL0 00TRUE00
2026-04-17250CALL0 024.14TRUE00
2026-04-1727.50CALL0 014.36TRUE00
2026-04-17300CALL0 021.06TRUE00
2026-04-1732.50CALL0 026.86TRUE00
2026-04-17352.42CALL0 128.9FALSE00
2026-04-1737.50CALL0 058.42FALSE00
2026-04-17400CALL0 045.07FALSE00
2026-04-1742.50CALL0 049.72FALSE00
2026-04-17450CALL0 078.71FALSE00
2026-04-1747.50CALL0 084.05FALSE00
2026-04-1717.50PUT0 0165.16FALSE00
2026-04-17200PUT0 0142.18FALSE00
2026-04-1722.50PUT0 084.34FALSE00
2026-04-17250PUT0 0105.28FALSE00
2026-04-1727.50.5PUT3 8629.44FALSE0.50
2026-04-17300PUT0 047.42FALSE00
2026-04-1732.50PUT0 037.63FALSE00
2026-04-17350PUT0 035.66TRUE00
2026-04-1737.50PUT0 030.8TRUE00
2026-04-17400PUT0 027.47TRUE00
2026-04-1742.50PUT0 034.03TRUE00
2026-04-17450PUT0 034.53TRUE00
2026-04-1747.50PUT0 041.7TRUE00

Latest GLPG Trades:

Date Shares Price
Jun 13, 2022 7:58 PM EST100$54.06
Jun 13, 2022 7:58 PM EST10$53.98
Jun 13, 2022 7:58 PM EST1$53.98
Jun 13, 2022 7:59 PM EST1$53.985
Jun 13, 2022 7:59 PM EST100$53.99

Galapagos NV (GLPG) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-086-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184320004215/0001171843-20-004215-index.htm
2020-01-27SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1421876/000090221920000071/0000902219-20-000071-index.htm
2019-07-17SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1421876/000110465919040709/0001104659-19-040709-index.htm
2019-07-23SC 13DGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1421876/000110465919041473/0001104659-19-041473-index.htm
2019-08-29SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1421876/000110465919047927/0001104659-19-047927-index.htm
2019-11-01SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1421876/000110465919059005/0001104659-19-059005-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1421876/000110465920021860/0001104659-20-021860-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1421876/000114036120003311/0001140361-20-003311-index.htm
2019-05-316-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184319003728/0001171843-19-003728-index.htm
2019-06-116-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184319003920/0001171843-19-003920-index.htm
2019-06-176-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184319004030/0001171843-19-004030-index.htm
2019-06-216-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184319004093/0001171843-19-004093-index.htm
2019-07-026-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184319004317/0001171843-19-004317-index.htm
2019-07-156-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184319004585/0001171843-19-004585-index.htm
2019-07-196-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184319004659/0001171843-19-004659-index.htm
2019-09-056-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184319005832/0001171843-19-005832-index.htm
2019-09-056-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184319005833/0001171843-19-005833-index.htm
2019-09-196-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184319006023/0001171843-19-006023-index.htm
2019-09-236-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184319006051/0001171843-19-006051-index.htm
2019-09-256-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184319006114/0001171843-19-006114-index.htm
2019-10-086-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184319006401/0001171843-19-006401-index.htm
2019-10-116-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184319006466/0001171843-19-006466-index.htm
2019-10-286-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184319006850/0001171843-19-006850-index.htm
2019-10-296-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184319006892/0001171843-19-006892-index.htm
2019-11-046-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184319007092/0001171843-19-007092-index.htm
2019-11-066-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184319007260/0001171843-19-007260-index.htm
2019-11-126-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184319007410/0001171843-19-007410-index.htm
2019-11-146-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184319007516/0001171843-19-007516-index.htm
2019-11-196-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184319007642/0001171843-19-007642-index.htm
2019-11-266-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184319007826/0001171843-19-007826-index.htm
2019-12-096-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184319008012/0001171843-19-008012-index.htm
2019-12-206-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184319008255/0001171843-19-008255-index.htm
2020-01-106-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184320000139/0001171843-20-000139-index.htm
2020-01-106-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184320000140/0001171843-20-000140-index.htm
2020-01-136-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184320000174/0001171843-20-000174-index.htm
2020-01-156-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184320000237/0001171843-20-000237-index.htm
2020-01-246-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184320000469/0001171843-20-000469-index.htm
2020-01-296-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184320000556/0001171843-20-000556-index.htm
2020-03-176-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184320001794/0001171843-20-001794-index.htm
2020-04-166-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184320002640/0001171843-20-002640-index.htm
2020-04-176-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184320002674/0001171843-20-002674-index.htm
2020-04-176-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184320002689/0001171843-20-002689-index.htm
2020-05-266-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184320003977/0001171843-20-003977-index.htm
2020-05-296-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184320004053/0001171843-20-004053-index.htm
2020-06-046-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184320004164/0001171843-20-004164-index.htm
2020-06-086-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184320004215/0001171843-20-004215-index.htm
2020-07-246-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184320005194/0001171843-20-005194-index.htm
2020-08-136-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184320005906/0001171843-20-005906-index.htm
2020-08-196-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184320005998/0001171843-20-005998-index.htm
2020-08-266-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184320006087/0001171843-20-006087-index.htm
2020-09-116-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184320006405/0001171843-20-006405-index.htm
2020-09-216-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184320006525/0001171843-20-006525-index.htm
2020-09-256-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184320006651/0001171843-20-006651-index.htm
2020-09-286-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184320006681/0001171843-20-006681-index.htm
2020-09-306-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184320006727/0001171843-20-006727-index.htm
2020-10-136-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184320007002/0001171843-20-007002-index.htm
2020-10-156-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184320007061/0001171843-20-007061-index.htm
2020-10-276-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184320007261/0001171843-20-007261-index.htm
2020-11-036-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184320007481/0001171843-20-007481-index.htm
2020-11-066-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184320007726/0001171843-20-007726-index.htm
2019-08-296-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000119312519234109/0001193125-19-234109-index.htm
2019-09-206-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000119312519250691/0001193125-19-250691-index.htm
2019-10-236-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000119312519272244/0001193125-19-272244-index.htm
2019-10-256-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000119312519274853/0001193125-19-274853-index.htm
2020-03-276-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000119312520088879/0001193125-20-088879-index.htm
2020-04-296-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000119312520126328/0001193125-20-126328-index.htm
2020-05-116-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000119312520139028/0001193125-20-139028-index.htm
2020-10-09S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1421876/000119312520267249/0001193125-20-267249-index.htm
2019-07-256-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000155837019006344/0001558370-19-006344-index.htm
2020-03-2720-FAnnual and transition report of foreign private issuers [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1421876/000155837020003270/0001558370-20-003270-index.htm
2020-08-066-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000155837020009632/0001558370-20-009632-index.htm